The severe acute respiratory syndrome coronavirus 2, the agent of the ongoing coronavirus disease 2019 (COVID‐19) pandemic, has spread worldwide since it was first identified in November 2019 in Wuhan, China. Since then, progress in pathogenesis linked severity of this systemic disease to the hyperactivation of network of cytokine‐driven pro‐inflammatory cascades. Here, we aimed to identify molecular biomarkers of disease severity by measuring the serum levels of inflammatory mediators in a Brazilian cohort of patients with COVID‐19 and healthy controls (HCs). Critically ill patients in the intensive care unit were defined as such by dependence on oxygen supplementation (93% intubated and 7% face mask), and computed tomography profiles showing ground‐glass opacity pneumonia associated to and high levels of D‐dimer. Our panel of mediators included HMGB1, ATP, tissue factor, PGE2, LTB4, and cys‐LTs. Follow‐up studies showed increased serum levels of every inflammatory mediator in patients with COVID‐19 as compared to HCs. Originally acting as a transcription factor, HMGB1 acquires pro‐inflammatory functions following secretion by activated leukocytes or necrotic tissues. Serum levels of HMGB1 were positively correlated with cys‐LTs, D‐dimer, aspartate aminotransferase, and alanine aminotransferase. Notably, the levels of the classical alarmin HMGB1 were higher in deceased patients, allowing their discrimination from patients that had been discharged at the early pulmonary and hyperinflammatory phase of COVID‐19. In particular, we verified that HMGB1 levels above 125.4 ng/ml is the cutoff that distinguishes patients that are at higher risk of death. In conclusion, we propose the use of serum levels of HMGB1 as a biomarker of severe prognosis of COVID‐19.
Neutrophils are multifaceted cells that, upon activation, release meshes of chromatin associated with different proteins, known as neutrophil extracellular traps (NETs). Leishmania amazonensis promastigotes and amastigotes induce NET release, and we have identified the signaling pathways involved in NET extrusion activated by promastigotes. Amastigotes maintain the infection in vertebrate hosts, and we have shown the association of NETs with amastigotes in human biopsies of cutaneous leishmaniasis. However, the interaction of amastigotes and neutrophils remains poorly understood. Our study aimed to characterize the pathways involved in the formation of NETs induced by axenic amastigotes from L. infantum, the causal agent of visceral leishmaniasis. Human neutrophils pretreated with signaling pathway inhibitors were incubated with amastigotes, and NET release was quantified in the culture supernatant. Amastigote viability was checked after incubation with NETs. We found that the release of NETs by neutrophils stimulated with these amastigotes requires the participation of elastase and peptidyl arginine deaminase and the involvement of PI3K, ROS, and calcium. Moreover, amastigotes are not susceptible to NET-mediated killing. Altogether, these findings improve our comprehension of the signaling pathways implicated in the interaction between amastigotes and human neutrophils.
SARS-CoV-2, the causative agent of the ongoing COVID-19, has spread worldwide since it was first identified in November 2019 in Wuhan. Since then, it was already demonstrated an exuberant inflammation, cytokine storm, endothelium dysfunction, platelets hyperactivation and aggregation, following T cell exhaustion leading to severe multi-organ damage and death of COVID-19 patients. Here, we sought to identify molecular biomarkers of disease severity in a Brazilian cohort of COVID-19 patients by measuring the serum levels of endogenous danger signals. Our data revealed that ICU patients that are critically ill, at the early hyperinflammatory phase of COVID-19 (around 12-25 days after hospital admission) display higher serum levels of the classical alarmin HMGB1. Serum levels of HMGB1 were positively correlated with cys-leukotrienes, D-dimer, AST, and ALT. Notably, we verified that HMGB1 levels above 125.4 ng/mL is the cut off that distinguishes the patients that are at higher risk of death. Serum levels of extracellular ATP, PGE 2 , LTB 4 , cys-LTs, and tissue factor were also elevated in the serum of ICU patients. In conclusion, we propose that serum levels of HMGB1 serve as prognostic biomarker of risk of death in patients suffering from severe COVID-19.
Background and Purpose: Chronic wounds are a major complication of diabetes mellitus (DM), posing a significant burden on healthcare systems worldwide. Despite advances in the field over the past two decades, the incidence of lower-limb amputations due to diabetes remains high. Persistent hyperglycemia sustains a chronic low-grade inflammation, disrupts hormonal homeostasis, and elevates glucocorticoid (GC) levels both systemically and locally, all of which impair wound healing. The enzymes 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and steroid 11β-hydroxylase (CYP11B1) are key mediators of local GC reactivation and production, respectively, and are upregulated in diabetic wounds. Experimental Approach: To investigate the therapeutic potential of metyrapone (MET), a dual 11β-HSD1/CYP11B1 inhibitor, as a topical pro-healing agent we used a full-thickness excisional wound model in alloxan-induced diabetic mice. Key
Results: Daily topical application of MET (1 mg/wound) for 14 days accelerated wound closure, reduced neutrophilic infiltration, restored myofibroblast differentiation, and enhanced collagen deposition. MET suppressed the expression of several pro-inflammatory genes and production of cytokines, such as IL-1β and IL-6, while reducing local GC production in the skin, without affecting its systemic levels. In
vitro , MET enhanced fibroblast migration without altering proliferation. Gene silencing via siRNA revealed that both 11β-HSD1 and CYP11B1 contributed to local GC production. Conclusions and
Implications: Collectively, these findings support MET as a promising topical therapeutic strategy to improve wound healing in diabetic patients.
Infection is a major complication of wound healing worldwide, with Staphylococcus aureus being the most isolated bacterial species from infected wounds. Pattern recognition receptors, such as NOD-like receptor (NLR) family, play crucial roles in coordinating subsequent stages of wound-healing via specific cells activation through the production of cytokines, such as IL-1β, whose release is strongly dependent on inflammasome complex assembly and is critical for controlling the bacterial load. To investigate the role of NLR family members in infected wounds, NLRP3-, NLRP6-, and NLRP12-knockout mice were subjected to a full-thickness wound model followed by topical infection with S. aureus(2.5×106 CFU/100 µL). Interestingly, only genetic ablation of NLRP6 resulted in a significant delay in wound closure. Immunohistochemical analyses revealed a decrease in fibronectin, as well as type I and type III collagen fiber deposition on day 7 post-wounding in NLRP6-/- mice. In addition, in vitro, NLRP6-/- fibroblasts exhibited impaired migration without changes in cell proliferation. Both fibroblasts and macrophages isolated from NLRP6-/- mice released fewer cytokines when stimulated in vitro with S. aureus, resulting in diminished IL-1β and CXCL1 production. However, in vivo, NLRP6-/- had no effect on neutrophil infiltration or the bacterial load. These findings indicate that NLRP6 positively influences skin wound closure during S. aureus infection, modulates cell migration and pro-inflammatory cytokine secretion, and stimulates extracellular matrix production. Although NLRP6 does not directly affect bacterial clearance, NLRP6-/- mice appeared more susceptible to lesion development when cutaneous wounds were infected with S. aureus compared with the wild-type mice.